Targeting myeloid MIF/CD74 axis in metastatic melanoma – mechanisms, prognostication and therapeutic opportunities

Bidragets beskrivning

Melanoma is the 5th most prevalent form of cancer in Finland, where the inhabitants are predominantly light-skinned. In the advanced stages, melanoma cells spread from the primary site (mostly the skin) via the bloodstream to distant organs. On that stage, surgery, radiotherapy and chemotherapy are less effective. One approach to treat metastatic melanoma is immunotherapy, which boosts the body's natural defences to eliminate the cancer cells. However, several melanoma patients develop mechanisms of resistance to this therapy. We discovered that melanoma cells may produce a factor called MIF, which turn off the body's natural defences, impairing the effectiveness of immunotherapy. In this project, we will validate MIF as a tool to select those patients that are eligible to respond to immunotherapy. For those that are not eligible, we will develop adjuvant strategies that neutralize MIF to restore the body's ability to kill cancer cells, unleashing the full power of immunotherapy.
Visa mer

Startår

2020

Slutår

2026

Beviljade finansiering

Carlos Rogerio Figueiredo Orcid -palvelun logo
438 874 €

Rogerio De Figueiredo Orcid -palvelun logo
438 874 €

Andra beslut

358209
Akademiforskarens forskningskostnader(2023)
199 402 €
336530
Akademiforskarens forskningskostnader(2020)
300 022 €

Rollen i Finlands Akademis konsortium

Ledare

Finansiär

Finlands Akademi

Typ av finansiering

Akademiforskare

Övriga uppgifter

Finansieringsbeslutets nummer

330876

Vetenskapsområden

Biomedicinska vetenskaper

Forskningsområden

Biolääketieteet

Identifierade teman

cancer